Apogee Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Checking your notes…
Item 5. Other Information
Trading Plans
During the fiscal quarter ended September 30, 2024, no director or Section 16 officer adopted orterminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (in each case, as defined in Item 408(a) of Regulation S-K), except as described below.
On August 21, 2024, Dr. Michael Henderson, the Company's Chief Executive Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 210,000 shares of our common stock over a period ending August 14, 2025, subject to certain conditions.
On August 21, 2024, Dr. Carl Dambkowski, the Company's Chief Medical Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 109,035 shares of our common stock over a period ending December 31, 2025, comprising exercises of vested stock options and sales of shares of our common stock, subject to certain conditions.
On September 27, 2024, Jane Pritchett Henderson, the Company's Chief Financial Officer, adopted a trading plan intended to satisfy Rule 10b5-1(c) to sell up to 10,500 shares of our common stock over a period ending December 31, 2025, subject to certain conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.